Related Experiment Videos
Clinical implications of minimal disease in the bone marrow and peripheral blood in neuroblastoma
1Pediatric Surgery, Reproductive and Developmental Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Purpose:
In patients with neuroblastoma (NB), minimal disease (MD) in bone marrow (BM) and peripheral blood (PB) is thought to play an important role in metastasis. The current study was designed to evaluate the clinical implications of the detection of MD in NB at the initial diagnosis.
Methods:
Expression of the neuroendocrine protein gene product 9.5 (PGP9.5) and tyrosine hydroxylase (TH) mRNA in BM and PB obtained from 18 patients with NB was investigated by reverse transcriptase-polymerase chain reaction (RT-PCR).
Results:
MD was detected in the BM obtained from 4 of 14 localized NB patients and also in the PB from 2. However, it was found also in both the BM and PB obtained from all 4 patients with metastatic NB. Two of the 4 MD-positive patients with localized NB had metastatic recurrence after a complete tumor excision. They also had unfavorable biological prognostic factors compared with the other 2 who did not have recurrent disease.
Conclusion:
MD detected by RT-PCR in the BM and the PB of patients with NB thus suggests a risk for metastatic disease, which in association with other unfavorable biological features may indicate a poor prognosis.
Insights
Detecting minimal disease (MD) in bone marrow and peripheral blood of neuroblastoma patients indicates a higher risk for metastasis. This finding, combined with other factors, may predict a poorer prognosis in neuroblastoma (NB) patients.
Area of Science:
- Oncology
- Molecular Biology
- Pediatric Cancer Research
Background:
- Minimal disease (MD) in bone marrow (BM) and peripheral blood (PB) is implicated in neuroblastoma (NB) metastasis.
- Early detection of MD is crucial for understanding NB progression.
Purpose of the Study:
- To evaluate the clinical implications of detecting minimal disease (MD) in neuroblastoma (NB) patients at initial diagnosis.
- To assess the role of MD in bone marrow (BM) and peripheral blood (PB) in NB metastasis.
Main Methods:
- Investigated expression of PGP9.5 and TH mRNA using RT-PCR.
- Analyzed BM and PB samples from 18 neuroblastoma patients.
Main Results:
- MD was detected in 4/14 localized NB patients' BM and 2/14 patients' PB.
- All 4 metastatic NB patients had MD in both BM and PB.
- Two localized, MD-positive NB patients experienced metastatic recurrence and had unfavorable prognostic factors.
Conclusions:
- RT-PCR detection of MD in NB patients' BM and PB suggests a risk for metastatic disease.
- MD, alongside other unfavorable biological features, may indicate a poor prognosis for neuroblastoma patients.